Sign in

You're signed outSign in or to get full access.

Jiwon Kim

Vice President and Equity Research Analyst at Citi

Jiwon Kim is a Vice President and Equity Research Analyst at Citi, specializing in the biotechnology sector with a focus on gene therapy, rare diseases, and innovative biopharma companies. She covers specific firms including BioMarin Pharmaceutical, Sarepta Therapeutics, and Vertex Pharmaceuticals, boasting a strong performance track record with a 68% success rate on TipRanks, ranking in the top 10% of biotech analysts, and average returns of 22% per rating. Kim joined Citi in 2021 after previous roles at Jefferies as a research associate from 2018 to 2021 and at Leerink Partners earlier in her career starting in 2016, bringing over eight years of dedicated biotech equity research experience. She holds Series 7, 63, and 86/87 FINRA licenses, underscoring her professional credentials in securities analysis.

Jiwon Kim's questions to Arcturus Therapeutics Holdings (ARCT) leadership

Question · Q4 2025

Jiwon Kim, on behalf of Yigal Nochomovitz, asked about the Lung Clearance Index (LCI) assessment in the phase Ib CF study, what was observed, the expected level of improvement in phase IIb, and if the FDA reviewed the phase Ib LCI data.

Answer

Joseph Payne, President and CEO, confirmed LCI was assessed in phase Ib for safety/tolerability. Alan H. Cohen, Chief Medical Officer, noted challenges with small numbers in early studies but highlighted that the current 12-week study benefits from prior experience, CF Foundation support (natural history study for comparator), and improved LCI technologies. He expects the larger, longer study to provide more robust and interpretable data, correlating LCI improvements with HRCT mucus plug burden.

Ask follow-up questions

Fintool

Fintool can predict Arcturus Therapeutics Holdings logo ARCT's earnings beat/miss a week before the call